M&A Deal Summary |
|
|---|---|
| Date | 2017-07-12 |
| Target | Vynamic |
| Sector | Business Services |
| Buyer(s) | UDG Healthcare |
| Deal Type | Add-on Acquisition |
| Deal Value | 32M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Business Services |
| Employees | 9,000 |
| Revenue | 1.3B USD (2020) |
UDG Healthcare operates in two segments, Ashfield and Sharp. Ashfield is a global integrated healthcare services partner offering a breadth of services in advisory, marketing, communications, strategic engagement, and patient solutions. Sharp engages in contract packaging, clinical, manufacturing, and technology services. UDG Healthcare was founded in 1948 and is based in Dublin, the Republic of Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 26 of 32 |
| Sector: Business Services M&A | 7 of 10 |
| Type: Add-on Acquisition M&A Deals | 21 of 26 |
| State: Pennsylvania M&A | 5 of 5 |
| Country: United States M&A | 8 of 13 |
| Year: 2017 M&A | 3 of 5 |
| Size (of disclosed) | 10 of 25 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-23 |
sellxpert & Co. KG
Speyer, Germany sellxpert GmbH & Co. KG is a German and Swiss contract sales outsourcing business, based in Speyer, Germany and Basel, Switzerland, respectively. Sellxpert provides innovative sales and marketing services to national and international healthcare and pharmaceutical companies across Germany and Switzerland, complimenting Ashfield’s existing services in the DACH region. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-17 |
Cambridge BioMarketing Group
Cambridge, Massachusetts, United States Cambridge BioMarketing is a provider of strategic launch and marketing solutions for orphan and rare disease products. Cambridge BioMarketing’s primary service offerings include: launch readiness support, digital strategy, market analytics, integrated marketing, patient identification and acquisition, medical affairs support, line extensions and patient retention and adherence programmes. Its customers are predominantly pharmaceutical and biotech companies. |
Buy | $35M |